發(fā)布時(shí)間：2018-11-08 15:38

【摘要】：本草乳炎清散是內(nèi)蒙古華天制藥有限公司自主研發(fā)的獸用天然藥物復(fù)方制劑,具有清熱解毒,消癰散結(jié),消腫止痛,托毒排膿的功效。目的:通過進(jìn)行奶牛乳房炎病原菌分離鑒定、本草乳炎清散體外抑菌、抗炎、急性毒性和臨床治療試驗(yàn),評(píng)價(jià)本草乳炎清散針對(duì)奶牛乳房炎的臨床治療效果及其對(duì)機(jī)體毒性強(qiáng)弱,為本草乳炎清散的臨床應(yīng)用提供科學(xué)依據(jù)。方法:(1)試驗(yàn)運(yùn)用小鼠耳廓腫脹模型、皮下棉球炎性肉芽腫增生模型和腹腔內(nèi)血管在醋酸刺激下通透性升高模型,觀察本草乳炎清散對(duì)炎癥的消除作用;(2)通過對(duì)乳樣進(jìn)行細(xì)菌分離純化,利用染色、鏡檢進(jìn)行形態(tài)學(xué)觀察以及生化實(shí)驗(yàn)鑒定乳樣中的病原菌;(3)選擇牛津小杯法檢測(cè)本草乳炎清散對(duì)奶牛乳房炎主要致病菌的抑菌圈大小;試管倍比稀釋法確定最小抑菌濃度(MIC)和最小殺菌濃度(MBC);(4)選擇測(cè)定小鼠對(duì)本草乳炎清散的最大耐受量(MTD)和最大耐受量倍數(shù)進(jìn)行安全性評(píng)價(jià);(5)經(jīng)混飼投喂本草乳炎清散,通過臨床治愈率、有效率,評(píng)價(jià)其對(duì)奶牛乳房炎的臨床治療效果。結(jié)果:(1)抗炎試驗(yàn):本草乳炎清散高、中、低劑量組耳廓腫脹抑制率分別為39.74%、36.78%和28.84%,與生理鹽水對(duì)照組相比,高、中劑量組存在極顯著性差異(P0.01),低劑量組存在顯著性差異(P0.05);本草乳炎清散高、中、低劑量組小鼠肉芽腫增生抑制率分別為53.53%、51.69%和35.89%,與生理鹽水對(duì)照組相比,高、中、低劑量組均存在極顯著性差異(P0.01);本草乳炎清散高、中、低劑量組對(duì)小鼠腹腔毛細(xì)血管通透性升高抑制率分別為51.06%、46.81%和34.04%,與生理鹽水對(duì)照組相比,高、中劑量組存在極顯著性差異(P0.01),低劑量組存在顯著性差異(P0.05);(2)細(xì)菌分離鑒定:共得到141株細(xì)菌,4個(gè)種類:無乳鏈球菌、金黃色葡萄球菌、大腸埃希菌和表皮葡萄球菌,檢出率分別為:46.10%、24.11%、20.57%和9.22%;(3)體外抑菌試驗(yàn):本草乳炎清散對(duì)金黃色葡萄球菌、大腸埃希菌、無乳鏈球菌的MIC分別為0.0625、0.125、0.0625g·mL-1;MBC分別為0.125、0.250、0.125g·mL-1。本草乳炎清散(0.50g·mL-1)對(duì)金黃色葡萄球菌、大腸埃希菌、無乳鏈球菌的抑菌圈直徑分別為22.83、21.60、24.51mm,均大于20mm,極敏感。(4)急性毒性試驗(yàn):本草乳炎清散對(duì)小鼠的最大耐受量為600mg/10g BW,最大耐受量倍數(shù)為150倍,屬于實(shí)際無毒,安全性較高;(5)臨床治療試驗(yàn):本草乳炎清散高、中劑量組治療有效率均達(dá)100%,且低劑量組的有效率高于公英散對(duì)照組。結(jié)論:本草乳炎清散對(duì)炎癥有很好的消除作用,對(duì)奶牛乳房炎主要致病菌的抑制效果明顯,在正常使用劑量內(nèi)安全性好,能夠有效治療對(duì)奶牛乳房炎。
[Abstract]:Ru Yan Qing San is a natural veterinary medicine compound preparation independently developed by Inner Mongolia Huatian Pharmaceutical Co., Ltd. It has the effect of clearing heat and detoxification, eliminating carbuncle, eliminating swelling and relieving pain, holding poison and discharging pus. Objective: to isolate and identify the pathogenic bacteria of dairy cow mastitis, and to investigate the effect of Ruyangqing powder on the inhibition, anti-inflammatory, acute toxicity and clinical treatment of dairy cow mastitis in vitro. To evaluate the clinical therapeutic effect of Bencao Ruyanqing Powder (BRYQS) on dairy cow mastitis and to provide scientific basis for clinical application of Bencao Ruyan Qingsan. Methods: (1) the mice auricle swelling model, subcutaneous cotton ball inflammatory granulomatous hyperplasia model and the model of increased permeability of intraperitoneal blood vessels stimulated by acetic acid were used to observe the anti-inflammatory effect of Bencao Ruyanqing Powder. (2) the bacteria in milk samples were isolated and purified, the pathogens in milk samples were identified by staining, microscopic observation and biochemical experiments. (3) the inhibition circle size of the main pathogenic bacteria of dairy cow mastitis was detected by Oxford small cup method, and the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC);) were determined by tube doubling dilution method. (4) to evaluate the safety of the maximum tolerance dose (MTD) and the maximum tolerance dose (multiple) of Ruyanqing Powder in mice. (5) to evaluate the clinical treatment of dairy cow mastitis through the clinical cure rate and effective rate. Results: (1) Anti-inflammatory test: the inhibition rates of auricle swelling in the high, middle and low dose groups were 39.74% and 28.84%, respectively, which were higher than those in the normal saline control group. There was significant difference in middle dose group (P0.01) and low dose group (P0.05). The inhibition rates of granulomatous proliferation were 53.53% and 35.89% in the high, medium and low dose groups, respectively. Compared with the normal saline control group, the inhibition rates of granulomatous proliferation were significantly higher (P0.01). The inhibition rates of high, medium and low dose groups on the increase of celiac capillary permeability in mice were 51.06% and 34.04%, respectively, which were higher than those in normal saline group. There was significant difference in middle dose group (P0.01) and low dose group (P0.05). (2) bacterial isolation and identification: a total of 141 strains of bacteria were obtained, four species: Streptococcus lactococcus, Staphylococcus aureus, Escherichia coli and Staphylococcus epidermidis, the detection rates were: 46.1010, 24.11, 20.57% and 9.22, respectively; (3) in vitro bacteriostasis test: the MIC of Ruyangqing Powder against Staphylococcus aureus, Escherichia coli and Streptococcus lactococcus were 0.06250.125 ~ 0.0625g mL-1;MBC = 0.1250.250,0.125g mL-1., respectively. The bacteriostasis diameter of RYQS (0.50g mL-1) against Staphylococcus aureus, Escherichia coli and Streptococcus lactobacillus were 22.83 ~ 21.60 ~ 24.51 mm, > 20mm, respectively. (4) Acute toxicity test: the maximum tolerance dose of RUYQS to mice was 150 times that of 600mg/10g BW, which was non-toxic and safe. (5) Clinical treatment trial: the effective rate of low dose group was higher than that of Gongying powder group, the effective rate of middle dose group was 100 kum, and the effective rate of low dose group was higher than that of Gongying powder group. Conclusion: Bencao Ruyanqing Powder has a good effect on the elimination of inflammation and has obvious inhibitory effect on the main pathogenic bacteria of mastitis in dairy cattle. It is safe in the normal dosage and can effectively treat the mastitis of dairy cow.
【學(xué)位授予單位】：西北農(nóng)林科技大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：S858.23

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 郝景鋒;李靜姬;張宇航;尹柏雙;付連軍;黃巖;李心慰;李小兵;趙晨旭;劉國文;;吉林省奶牛乳房炎發(fā)病情況調(diào)查[J];中國獸醫(yī)雜志;2017年01期

2 李新圃;李宏勝;羅金印;楊峰;王旭榮;;奶牛乳房炎致病菌的分離鑒定及耐藥性研究[J];動(dòng)物醫(yī)學(xué)進(jìn)展;2015年11期

3 張寶s，

本文編號(hào)：2318914